Amgen (AMGN) — Profile, ISIN & Live Price

Amgen Inc. is a prominent American multinational biopharmaceutical company based in Thousand Oaks, California, recognized for its significant contributions to the biotechnology sector. Renowned for its focus on innovative therapies, Amgen specializes in the development of medications targeting serious illnesses, particularly in areas such as oncology, nephrology, and inflammation. The company is a leader in producing biologic drugs, with a portfolio that includes well-known products like Enbrel, Neulasta, and Prolia. As one of the largest biomedical companies globally by revenue, Amgen continues to enhance its market position through advancements in drug discovery and development, particularly in small molecule therapies.

Recently, Amgen has faced challenges that have impacted its operations and product reputation. The European regulator's call for the revocation of authorization for its drug Tavneos, coupled with a retraction of a pivotal study article in a medical journal, has complicated the company's defense efforts regarding the drug's efficacy and safety. Additionally, Amgen's legal landscape has been affected by a loss in a patent case related to its antibody technology, resulting in a significant financial penalty. Despite these setbacks, the company remains committed to advancing its research capabilities and maintaining its leadership in the biopharmaceutical industry.